scholarly journals Malignant Myoepithelial Carcinoma Expleomorphic Adenoma of the Hard Palate: An Aggressive Tumor with Diagnostic Dilemma

2014 ◽  
Vol 5 (2) ◽  
pp. 72-77
Author(s):  
Sudhir Naik ◽  
Rajshekar Halkud ◽  
KT Siddappa ◽  
Akshay Shivappa ◽  
Siddharth Biswas ◽  
...  
Keyword(s):  
Pleomorphic Adenoma ◽  
Hard Palate ◽  
De Novo ◽  
Metastatic Tumor ◽  
Myoepithelial Cells ◽  
Concurrent Chemotherapy ◽  
Adjuvant Chemoradiotherapy ◽  
Myoepithelial Carcinoma ◽  
Diagnostic Dilemma ◽  
Aggressive Tumor

ABSTRACT Background/Objectives Myoepithelial carcinomas are uncommon neoplasms that account for about 10% of all myoepitheliomas. The invasiveness varies from a locally aggressive to highly metastatic tumor which may arise de novo or in a pleomorphic adenoma. Myoepitheliomas arise from myoepithelial cells lacking ductal differentiation which exhibit both epithelial and smooth muscle cell elements. Case report We report a case of palatal swelling excised 4 years back, as pleomorphic adenoma, which later recurred as malignant myoepithelial carcinoma expleomorphic adenoma of the palate. CECT of the paranasal air sinuses did not show any bony invasion of the hard palate. So he was given radical radiotherapy with concurrent chemotherapy but after 3 years developed recurnce and metastasis to the skin and the lungs. The patient was referred to oral chemotherapy on a palliative basis. Conclusion Malignant myoepithelial carcinoma expleomorphic adenoma of the hard palate is a highly aggressive rare tumor of the hard palate. Radical management with surgery and adjuvant chemoradiotherapy improves survival in these patients. Followup with metastatic workup should be accurate as the tumor is highly aggressive with poor prognosis. How to cite this article Shenoy AM, Halkud R, Shivappa A, Chavan p, Sunil KC, Sarvadyna J, Samskruthi M, Siddappa KT, Biswas S, Naik SM. Malignant Myoepithelial Carcinoma Expleomorphic Adenoma of the Hard palate: An Aggressive Tumor with Diagnostic Dilemma. Int J Head Neck Surg 2014;5(2):72-77.

scholarly journals Cystic and florid squamous metaplasia in pleomorphic adenoma of palate – A diagnostic dilemma

2014 ◽  
Vol 5 (4) ◽  
pp. 108-110 ◽  
Author(s):  
H Kaveri ◽  
K Gopalkrishnana ◽  
Anehosur Venkatesh
Keyword(s):  
Pleomorphic Adenoma ◽  
Myoepithelial Cell ◽  
Benign Tumor ◽  
Squamous Metaplasia ◽  
Myoepithelial Cells ◽  
Cystic Degeneration ◽  
Minor Trauma ◽  
Medical Sciences ◽  
Diagnostic Dilemma

Pleomorphic adenoma is a benign tumor of salivary gland. Controversy regarding the origin of various mesenchymal components exists and myoepithelial cell has a key role. Metaplastic process is triggered by minor trauma and probable etiology for this change is ischemia. It is diagnostically challenging, because diagnostic pit falls in the presence of mucinous and squamous metaplasia. Report a case of pleomorphic adenoma in the palate of a 35 years old Indian female. Biopsy revealed epithelial component with extensive squamous metaplasia and cystic degeneration. Here we discuss the role of myoepithelial cells in the pathogenesis of pleomorphic adenoma and diagnostic pit falls. DOI: http://dx.doi.org/10.3126/ajms.v5i4.10434 Asian Journal of Medical Sciences 2014 Vol.5(4); 108-110

scholarly journals Epithelial-Myoepithelial Carcinoma of The Minor Salivary Glands: Report of Two Cases with Literature Review

2021 ◽  
Author(s):  
Kohei Okuyama ◽  
Yasuyuki Michi ◽  
Yoshihisa Kashima ◽  
Hirofumi Tomioka ◽  
Hideaki Hiral ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Literature Review ◽  
Salivary Glands ◽  
Pleomorphic Adenoma ◽  
Hard Palate ◽  
Tumor Resection ◽  
Myoepithelial Carcinoma ◽  
Incisional Biopsy ◽  
Minor Salivary Glands ◽  
Epithelial Myoepithelial Carcinoma

Abstract Epithelial-myoepithelial carcinoma (EMC) is a rare malignant salivary gland tumor, which is especially uncommon in the minor salivary glands (MSG). We report literature review of EMC of the MSGs with our experience of two cases. Case 1 is a 75-year-old woman with a hard elastic mass in the hard palate, sized 2.5 × 2 cm without ulceration. Incisional biopsy was suggestive of pleomorphic adenoma. Tumor resection was performed with adequate surgical margin. Case 2 is a 44-year-old woman with a mass in the hard palate, sized 1.8 × 1.6 cm without ulceration. Incisional biopsy was suggestive of pleomorphic adenoma or a low-grade salivary gland carcinoma and intraoral tumor resection was performed. Both have good postoperative courses and are alive with no evidence of local recurrence or metastasis at 25 and 10 months. The Ki-67 labeling index in Case 1 and 2 were 10.6 and 3.8 %. Considering that the anatomy, structure, and size of salivary glands are quite different from MSGs, EMCs of the MSG cannot be predicted similarly to EMCs of the major salivary glands. The present review with 18 cases revealed no consensus on treatment methods for MSG cases other than surgery.

scholarly journals A case of myoepithelial carcinoma ex pleomorphic adenoma of the hard palate

2015 ◽  
Vol 61 (3) ◽  
pp. 173-176
Author(s):  
Kazuhiro OGI ◽  
Jun-ichi KOBAYASHI ◽  
Kousuke TAKEDA ◽  
Takashi IDE ◽  
Akihiro MIYAZAKI ◽  
...  
Keyword(s):  
Pleomorphic Adenoma ◽  
Hard Palate ◽  
Carcinoma Ex Pleomorphic Adenoma ◽  
Myoepithelial Carcinoma

scholarly journals A Rare De Novo Myoepithelial Carcinoma Ex Pleomorphic Adenoma in a Young Woman

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Geeta Ahuja ◽  
Delaram J. Taghipour ◽  
Olubode A. Olufajo ◽  
Bonnie C. Davis ◽  
Babak Shokrani ◽  
...  
Keyword(s):  
Parotid Gland ◽  
Pleomorphic Adenoma ◽  
De Novo ◽  
Myoepithelial Cells ◽  
Young Female ◽  
Accurate Diagnosis ◽  
Carcinoma Ex Pleomorphic Adenoma ◽  
Gland Carcinoma ◽  
Uncommon Neoplasm ◽  
Parotid Gland Carcinoma

Carcinoma ex pleomorphic adenoma, an uncommon neoplasm of the parotid gland, accounts for less than 4% of salivary gland tumors. It arises from a benign pleomorphic adenoma presenting in the sixth to eighth decades of life. We present this as a unique account of a primary parotid gland carcinoma, arising from myoepithelial cells, without a known precursor lesion, in a 28-year-old woman. This presentation seeks to provide familiarity of an unusual presentation of an unexpected rare pathology in a young female patient and the tools utilized for an accurate diagnosis.

scholarly journals Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma

2021 ◽  
Vol 14 (3) ◽  
pp. 280
Author(s):  
Rita Rebelo ◽  
Bárbara Polónia ◽  
Lúcio Lara Santos ◽  
M. Helena Vasconcelos ◽  
Cristina P. R. Xavier
Keyword(s):  
Clinical Trials ◽  
Drug Development ◽  
Pancreatic Ductal Adenocarcinoma ◽  
De Novo ◽  
Drug Repurposing ◽  
Metastatic Tumor ◽  
Therapeutic Options ◽  
Ductal Adenocarcinoma ◽  
Clinical Indication ◽  
Novel Treatments

Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest tumors worldwide. The diagnosis is often possible only in the latter stages of the disease, with patients already presenting an advanced or metastatic tumor. It is also one of the cancers with poorest prognosis, presenting a five-year survival rate of around 5%. Treatment of PDAC is still a major challenge, with cytotoxic chemotherapy remaining the basis of systemic therapy. However, no major advances have been made recently, and therapeutic options are limited and highly toxic. Thus, novel therapeutic options are urgently needed. Drug repurposing is a strategy for the development of novel treatments using approved or investigational drugs outside the scope of the original clinical indication. Since repurposed drugs have already completed several stages of the drug development process, a broad range of data is already available. Thus, when compared with de novo drug development, drug repurposing is time-efficient, inexpensive and has less risk of failure in future clinical trials. Several repurposing candidates have been investigated in the past years for the treatment of PDAC, as single agents or in combination with conventional chemotherapy. This review gives an overview of the main drugs that have been investigated as repurposing candidates, for the potential treatment of PDAC, in preclinical studies and clinical trials.

scholarly journals Pleomorphic adenoma of the hard palate

2013 ◽  
Vol 2013 (apr09 1) ◽  
pp. bcr2013008969-bcr2013008969 ◽  
Author(s):  
M. Gupta ◽  
M. Gupta
Keyword(s):  
Pleomorphic Adenoma ◽  
Hard Palate

Two sides of the same coin: Insights into the myoepithelial cells in carcinoma ex pleomorphic adenoma development

2021 ◽  
Vol 157 ◽  
pp. 103195
Author(s):  
João Figueira Scarini ◽  
Erika Said Abu Egal ◽  
Reydson Alcides de Lima-Souza ◽  
Lívia Ramalho Crescencio ◽  
Carolina Emerick ◽  
...  
Keyword(s):  
Pleomorphic Adenoma ◽  
Myoepithelial Cells ◽  
Carcinoma Ex Pleomorphic Adenoma ◽  
Two Sides

scholarly journals Giant Cell Carcinosarcoma of the Parotid Gland With a PLAG 1 Translocation in Association With a Pleomorphic Adenoma With HMGA2 Translocation

2020 ◽  
Vol 154 (6) ◽  
pp. 811-815
Author(s):  
Levon Katsakhyan ◽  
Virginia A LiVolsi ◽  
Ara A Chalian ◽  
Paul J Zhang
Keyword(s):  
Salivary Gland ◽  
In Situ Hybridization ◽  
Parotid Gland ◽  
Giant Cell ◽  
Pleomorphic Adenoma ◽  
De Novo ◽  
Sarcomatous Component ◽  
Gland Tumor ◽  
Parotid Gland Tumor

Abstract Objectives Carcinosarcomas of the salivary gland are rare neoplasms and have been described arising de novo or in association with pleomorphic adenoma (PA). PLAG1 and HMGA2 translocations are known to occur in PAs and carcinomas ex PA but are mutually exclusive. Methods We report a case of a carcinosarcoma in the parotid gland of a 77-year-old man with unusual anaplastic sarcomatoid giant cell morphology. Results Microscopically, a small separate PA was found adjacent to the carcinosarcoma. By conventional notion, the PA and carcinosarcoma would be considered related, as carcinosarcomas are well known to arise from PAs (carcinosarcoma ex PA). However, fluorescence in situ hybridization (FISH) assay demonstrated PLAG1 translocation in the carcinosarcoma and HMGA2 translocation in the separate PA. Conclusions These findings support that the carcinosarcoma likely originated from another PA with a PLAG1 translocation or de novo but not from the coexisting PA harboring a different translocation. To our knowledge, the case is the first to demonstrate PLAG1 translocation by FISH in a sarcomatous component of any parotid gland tumor, which may help better classify these tumors. In addition, multiple PAs are commonly found in the salivary gland, and to our knowledge, our case is the first to demonstrate that the same parotid gland can host PAs and PA-related tumors with different translocations.

Hepatic Myoepithelial Carcinoma in a Dog: Immunohistochemical Comparison With Other Canine Hepatic Carcinomas

2019 ◽  
Vol 56 (6) ◽  
pp. 889-894
Author(s):  
Yuka Tsuji ◽  
Mizuki Kuramochi ◽  
Takeshi Izawa ◽  
Hideo Akiyoshi ◽  
Jyoji Yamate ◽  
...  
Keyword(s):  
Smooth Muscle Actin ◽  
Myoepithelial Cells ◽  
Left Lobe ◽  
Myoepithelial Carcinoma ◽  
Hepatic Tumors ◽  
Muscle Actin ◽  
Hepatic Carcinoma ◽  
Neoplastic Cells ◽  
Immunohistochemical Studies ◽  
Vacuolated Cytoplasm

An 11-year-old female miniature Dachshund dog presented with a solid, soft, gray mass on the hepatic lateral left lobe. Histologically, the mass consisted of neoplastic proliferation of cells with round nuclei and eosinophilic and vacuolated cytoplasm arranged in alveolar, trabecular, and solid patterns. Immunohistochemically, the neoplastic cells were positive for pancytokeratin (CK AE1/AE3), CK5, CK14, vimentin, Sox9, and myoepithelial markers (α–smooth muscle actin, p63, and calponin). The morphological and immunohistochemical findings indicated a diagnosis of myoepithelial carcinoma. We conducted immunohistochemical studies on other representative canine hepatic tumors. Although the myoepithelial phenotype was not observed in the hepatocellular carcinoma, some tumor cells in cholangiocarcinoma showed immunohistochemical features of myoepithelium, suggesting that some neoplastic cells in cholangiocarcinoma may have the potential to differentiate into myoepithelial cells. To our knowledge, this is the first report in veterinary medicine of a hepatic carcinoma with a myoepithelial phenotype.

Sign in / Sign up

Export Citation Format

Share Document